Moll Wendén acts as legal advisor to AegirBio AB in connection with the signing of a sale and purchase agreement regarding acquisition of Dynamic Code AB (publ). Provided that all shareholders participate in the sale of shares and that all warrants are acquired, the purchase price will be of approximately SEK 1,5 billion in total. The purchase price shall be paid partly through a cash payment, and partly in shares in AegirBio.

The transaction is intended to be completed on 1 November 2021, whereupon AegirBio will issue shares through a share issue in kind pursuant to the authorisation granted by the general meeting. The acquisition is conditioned on completed due diligence as well as that 95 percent of the shareholders in Dynamic Code accede to the Sale and Purchase Agreement.

In connection with the acquisition, Moll Wendén advised AegirBio in a directed new issue of SEK 127.4 million. The capital injection from the new share issue as well as a loan financing of SEK 75 million is primarily intended to be used to finance the acquisition of Dynamic Code and to enable further acquisitions.

Dynamic Code develops and offers smart diagnostic and health care testing solutions for diseases based on rigourous DNA technology that is utilized in both traditional health care and for customers. Dynamic Code is a Linköping-based company with approximately 60 employees and a turnover of SEK 278 million.

AegirBio will, through the acquisition, expand its offer with an all-in-one complete solution that offers a total chain from test to treatment. Thus, AegirBio is strengthening its offering in the market for patient-centered tests with another company.

For more information, please see AegirBio’s press release here.

Moll Wendén’s team consisted of Mikael Karlsson (partner), Henric Stråth (partner), Julia Ekerot (associate), Alexandra Johansson (associate) and Andrea Gicic (associate).